OpenAI has acquired Orchestra Bio, a platform that helps biopharmaceutical teams coordinate drug development. The team and technology will be combined with OpenAI's AI models and tools.

In the US, the path from identifying a therapeutic target to drug approval takes 10-15 years on average. The company hopes AI will help shorten this time.